caa a22 4500 397560443 CHVBK 20180308164814.0 cr unu---uuuuu 161202e19960821xx s 000 0 eng 10.1093/jnci/88.16.1110 doi (NATIONALLICENCE)oxford-10.1093/jnci/88.16.1110 Clinicopathologic and Prognostic Significance of an Angiogenic Factor, Thymidine Phosphorylase, in Human Colorectal Carcinoma [Elektronische Daten] [Yuji Takebayashi, Shin-ichi Akiyama, Suminori Akiba, Kazutaka Yamada, Kazutaka Miyadera, Tomoyuki Sumizawa, Yuji Yamada, Fusayoshi Murata, Takashi Aikou] Background: Platelet-derived endothelial cell growth factor (PD-ECGF) is known to promote the development of new blood vessels, which are fundamental to tumor growth and metastasis. We previously found that thymidine phosphorylase (dThdPase) and PD-ECGF are the same protein. Purpose: We retrospectively examined the expression of dThdPase in primary colorectal carcinomas, its association with angiogenesis and clinicopathologic findings, and its prognostic value. Methods: Tissues were obtained from the tumors of 163 patients whose colorectal carcinomas were completely removed by surgery. Microvessels assessed by immunostaining endothelial cells for factor VIII were counted on a 400× field in the most active areas of neovascularization within the tumor. We purified the monoclonal antibody against dThdPase and studied the expression of dThdPase in the same serial sections used for the detection of factor VIII. Those who carried out microvessel counting and dThdPase expression assessment had no knowledge of clinicopathologic findings. The significance of dThdPase in the prognosis of patients with colorectal carcinomas was also examined in the survival analysis of mortality follow-up data covering the period between 1984 through 1991. Reported P values are from two-sided tests of statistical significance. Results: The mean microvessel count (± standard deviation) in dThdPase-positive colorectal carcinoma specimens (17.5 ± 7.2) was higher (P<.001) than that in dThdPase-negative carcinoma specimens (9.3 ± 5.5). The dThdPase positivity was in accordance with the microvessel count. dThdPase positivity showed highly significant statistical associations with tumor size, extent of invasion, lymph node metastasis, lymphatic invasion, and venous invasion. Cox regression analysis revealed that dThdPase expression was prognostic for poor disease outcome after adjustment for Dukes' stage and microvessel count. Conclusions: These findings suggest that higher levels of dThdPase expression in colorectal carcinomas are associated with more extensive angiogenesis, poor clinical and laboratory findings, and unfavorable clinical outcome. Implications: Inhibition of dThdPase in human colorectal carcinomas might improve prognosis for some patients. © Oxford University Press ARTICLES nationallicence Takebayashi Yuji Department of Cancer Chemotherapy, Institute for Cancer Research and First Department of Surgery, Faculty of Medicine, Kagoshima University Japan aut Akiyama Shin-ichi Department of Cancer Chemotherapy, Institute for Cancer Research, Faculty of Medicine, Kagoshima University Japan aut Akiba Suminori Department of Public Health, Faculty of Medicine, Kagoshima University Japan aut Yamada Kazutaka First Department of Surgery, Faculty of Medicine, Kagoshima University Japan aut Miyadera Kazutaka Department of Cancer Chemotherapy, Institute for Cancer Research. Kagoshima University and Taiho Pharmaceutical Co. Ltd. Saitama, Japan aut Sumizawa Tomoyuki Department of Cancer Chemotherapy, Institute for Cancer Research, Faculty of Medicine, Kagoshima University Japan aut Yamada Yuji Taiho Pharmaceutical Co. Ltd. aut Murata Fusayoshi Second Department of Anatomy, Faculty of Medicine, Kagoshima University Japan aut Aikou Takashi First Department of Surgery, Faculty of Medicine, Kagoshima University Japan aut JNCI: Journal of the National Cancer Institute Oxford University Press 88/16(1996-08-21), 1110-1117 0027-8874 88:16<1110 1996 88 jnci https://doi.org/10.1093/jnci/88.16.1110 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1093/jnci/88.16.1110 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Takebayashi Yuji Department of Cancer Chemotherapy, Institute for Cancer Research and First Department of Surgery, Faculty of Medicine, Kagoshima University Japan aut NATIONALLICENCE 700 1- Akiyama Shin-ichi Department of Cancer Chemotherapy, Institute for Cancer Research, Faculty of Medicine, Kagoshima University Japan aut NATIONALLICENCE 700 1- Akiba Suminori Department of Public Health, Faculty of Medicine, Kagoshima University Japan aut NATIONALLICENCE 700 1- Yamada Kazutaka First Department of Surgery, Faculty of Medicine, Kagoshima University Japan aut NATIONALLICENCE 700 1- Miyadera Kazutaka Department of Cancer Chemotherapy, Institute for Cancer Research. Kagoshima University and Taiho Pharmaceutical Co. Ltd. Saitama, Japan aut NATIONALLICENCE 700 1- Sumizawa Tomoyuki Department of Cancer Chemotherapy, Institute for Cancer Research, Faculty of Medicine, Kagoshima University Japan aut NATIONALLICENCE 700 1- Yamada Yuji Taiho Pharmaceutical Co. Ltd aut NATIONALLICENCE 700 1- Murata Fusayoshi Second Department of Anatomy, Faculty of Medicine, Kagoshima University Japan aut NATIONALLICENCE 700 1- Aikou Takashi First Department of Surgery, Faculty of Medicine, Kagoshima University Japan aut NATIONALLICENCE 773 0- JNCI: Journal of the National Cancer Institute Oxford University Press 88/16(1996-08-21), 1110-1117 0027-8874 88:16<1110 1996 88 jnci Metadata rights reserved CC BY-NC-4.0 http://creativecommons.org/licenses/by-nc/4.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-oxford